Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis

Area of Science:

• Neuroimmunology
• Microbiome Research

Background:

• Multiple sclerosis (MS) is a chronic central nervous system disease characterized by autoimmune inflammation and neurodegeneration.
• The gut microbiota's composition and function are increasingly recognized as potential contributing factors in MS pathogenesis.

Purpose of the Study:

• To review current evidence on gut dysbiosis in MS.
• To examine the links between gut dysbiosis, disease progression, immune response, and metabolic pathways in MS.
• To discuss therapeutic strategies targeting the gut microbiome for MS management.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of gut dysbiosis characteristics in MS patients.
• Examination of immune and metabolic alterations associated with gut dysbiosis in MS.

Main Results:

• Evidence suggests specific alterations in gut microbiota composition and function in individuals with MS.
• Gut dysbiosis is associated with disease course, immune dysregulation, and altered metabolic pathways in MS.
• Interventions targeting the gut microbiome show potential for managing MS.

Conclusions:

• Gut dysbiosis is a significant factor in multiple sclerosis.
• Modulating the gut microbiome offers promising therapeutic avenues for MS.
• Further research into microbiome-targeted therapies is warranted for MS treatment.